Turing Pharmaceuticals - Intranasal Ketamine Program - Ownership and Business Overview

Life ScienceCompany

Turing Pharmaceuticals - Intranasal Ketamine Program Ownership

Who owns Turing Pharmaceuticals - Intranasal Ketamine Program?

Turing Pharmaceuticals - Intranasal Ketamine Program is owned by Adhera Therapeutics. It was acquired on May 3, 2016.

Turing Pharmaceuticals - Intranasal Ketamine Program Business Overview

Where is Turing Pharmaceuticals - Intranasal Ketamine Program headquartered?

Turing Pharmaceuticals - Intranasal Ketamine Program is headquartered in New York, New York.

What sector is Turing Pharmaceuticals - Intranasal Ketamine Program in?

Turing Pharmaceuticals - Intranasal Ketamine Program is a life science company.

Life Science M&A Summary in 2016

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2016. The largest life science acquisition in 2016 was Baxalta - which was acquired by Shire for $32.0B.

Join Mergr to view all 295 acquisitions of life science companies in 2016, including 33 acquisitions by private equity firms, and 262 by strategics.

Turing Pharmaceuticals - Intranasal Ketamine Program

New York, New York 10036
United States,

Turing Pharmaceuticals - Intranasal Ketamine Program comprises business of developing intranasal ketamine to treat disorders due to stress. The asset is located in the United States.


 Subscribe to unlock this and 208,107
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.